Journal of Pain and Symptom Management
Volume 39, Issue 4 , Pages 756-767 , April 2010

A Systematic Review of the Treatment of Nausea and/or Vomiting in Cancer Unrelated to Chemotherapy or Radiation

This article was presented at the Ohio Hospice and Palliative Care Organization Conference, November 5, 2008, Columbus, OH, USA, and the Toronto Pain and Symptom Management Conference, November 22, 2008, Toronto, Ontario, Canada.

  • Mellar P. Davis, MD, FCCP

      Affiliations

    • The Harry R. Horvitz Center for Palliative Medicine, Division of Solid Tumor, The Taussig Cancer Center, The Cleveland Clinic, Cleveland, Ohio, USA
    • Palliative Medicine & Supportive Oncology Services, Division of Solid Tumor, The Taussig Cancer Center, The Cleveland Clinic, Cleveland, Ohio, USA
    • Corresponding Author InformationAddress correspondence to: Mellar P. Davis, MD, FCCP, Division of Solid Tumor, The Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center, The Cleveland Clinic, 9500 Euclid Avenue, R35, Cleveland, OH 44195, USA.
    • ,
  • Gretchen Hallerberg, MS, MSLS, AHIP

      Affiliations

    • Library, The Cleveland Clinic, Cleveland, Ohio, USA
    • ,
  • Palliative Medicine Study Group of the Multinational Association of Supportive Care in Cancer

,Accepted 4 August 2009.

References 

  1. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials. Current issues and further directions. Int J Technol Assess Health Care. 1996;12(2):195–208
  2. Moher D, Cook DJ, Jadad AR, et al. Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses. Health Technol Assess. 1999;3(12):i–iv1–98
  3. Cook DJ, Greengold NL, Ellrodt AG, Weingarten SR. The relation between systematic reviews and practice guidelines. Ann Intern Med. 1997;127(3):210–216
  4. Crowther MA, Cook DJ. Trials and tribulations of systematic reviews and meta-analyses. Hematology Am Soc Hematol Educ Program. 2007;493–497
  5. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482–2494
  6. Glare P, Pereira G, Kristjanson LJ, Stockler M, Tattersall M. Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer. Support Care Cancer. 2004;12(6):432–440[review]
  7. Bentley A, Boyd K. Use of clinical pictures in the management of nausea and vomiting: a prospective audit. Palliat Med. 2001;15(3):247–253
  8. Lichter I. Results of antiemetic management in terminal illness. J Palliat Care. 1993;9(2):19–21
  9. Stephenson J, Davies A. An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2006;14(4):348–353
  10. Jadad A, Moore A, Carroll D, Jeakinson C, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996;17:1–12
  11. Brown S, North D, Marvel MK, Fons R. Acupressure wrist bands to relieve nausea and vomiting in hospice patients: do they work?. Am J Hosp Palliat Care. 1992;9(4):26–29
  12. Bruera E, Belzile M, Neumann C, et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000;19(6):427–435
  13. Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: a randomized controlled trial. J Pain Symptom Manage. 2004;28(4):381–388
  14. Bruera ED, MacEachern TJ, Spachynski KA, et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer. 1994;74(12):3204–3211
  15. Corli O, Cozzolino A, Battaiotto L. Effectiveness of levosulpiride versus metoclopramide for nausea and vomiting in advanced cancer patients: a double-blind, randomized, crossover study. J Pain Symptom Manage. 1995;10(7):521–526
  16. Hardy J, Ling PJ, Mansi J, et al. Pitfalls in placebo-controlled trials in palliative care: dexamethasone for the palliation of malignant bowel obstruction. Palliat Med. 1998;12:437–442
  17. Hardy J, Daly S, McQuade B, et al. A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002;10(3):231–236
  18. Laval G, Girardier J, Lassauniere JM, et al. The use of steroids in the management of inoperable intestinal obstruction in terminal cancer patients: do they remove the obstruction?. Palliat Med. 2000;14(1):3–10
  19. Mercadante S, Ripamonti C, Casuccio A, Zecca E, Groff L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support Care Cancer. 2000;8(3):188–191
  20. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of tropisetron and chlorpromazine combinations in the control of nausea and vomiting of patients with advanced cancer. J Pain Symptom Manage. 1998;15(3):176–184
  21. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer. 1998;83(6):1214–1223
  22. Mystakidou K, Befon S, Trifyllis J, Liossi C, Papadimitriou J. Tropisetron versus metoclopramide in the control of emesis in far-advanced cancer. Oncologist. 1997;2(5):319–323
  23. Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial. Anticancer Res. 2002;22(2B):1187–1192
  24. Ripamonti C, Mercadante S, Groff L, et al. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom Manage. 2000;19(1):23–34
  25. Schunemann HJ, Jaeschke R, Cook DJ, et al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am J Respir Crit Care Med. 2006;174(5):605–614
  26. Oxford Centre for Evidence-Based Medicine. Levels of evidence and grades of recommendation. Available from: www.cebm.net/levels_of_evidence(last accessed date June 2008)
  27. Browne D. Vomiting mechanisms: a clinical study of thiethylperazine. South M J. 1961;54:953–961
  28. Bruera E, Michaud M, Partington J, et al. Continuous subcutaneous (CS) infusion of metoclopramide (MCP) using a plastic disposable infusor for the treatment of chemotherapy-induced emesis. J Pain Symptom Manage. 1988;3(2):105–107
  29. Bryson SM, McGovern EM, Kelman AW, et al. The pharmacokinetics of high dose metoclopramide in patients with neoplastic disease. Br J Clin Pharmacol. 1985;19(6):757–766
  30. Eisenchlas JH, Garrigue N, Junin M, De Simone GG. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med. 2005;19(1):71–75
  31. Fagnano G, Cristofari U. Use of prochlorperazine as adjuvant in therapy of secondary phenomena in cancer patients. Minerva Med. 1959;50(44):1748–1749
  32. Homburger F, Smithy G. Chlorpromazine in patients with nausea and vomiting due to advanced cancer. N Engl J Med. 1954;251(20):820–822
  33. Homburger F, Smithy G. Proclorperazine for the treatment of nausea and vomiting in patients with advanced cancer and other chronic diseases. N Engl J Med. 1957;256(1):27
  34. Kennett A, Hardy J, Shah S, A'Hern R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Support Care Cancer. 2005;13(9):715–721
  35. Khoo D, Hall E, Motson R, et al. Palliation of malignant intestinal obstruction using octreotide. Eur J Cancer. 1994;30A(1):28–30
  36. Mangili G, Franchi M, Mariani A, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996;61(3):345–348
  37. Passik SD, Lundberg J, Kirsh KL, et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage. 2002;23(6):526–532
  38. Philip J, Lickiss N, Grant PT, Hacker NF. Corticosteroids in the management of bowel obstruction on a gynecological oncology unit. Gynecol Oncol. 1999;74(1):68–73
  39. Ripamonti CI, Easson AM, Gerdes H. Management of malignant bowel obstruction. Eur J Cancer. 2008;44(8):1105–1115[review]
  40. Shima Y, Ohtsu A, Shirao K, Sasaki Y. Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction. Jpn J Clin Oncol. 2008;38(5):354–359
  41. Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med. 1999;60(8):568–570
  42. Weston G. Control of nausea and vomiting: observations on the use of chlor-trimeton (chlorprophenpyridamine malate) syrup. CA Med. 1957;86(6):378–380
  43. De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage. 1991;6(8):484–486
  44. Ventafridda V, Ripamonti C, Caraceni A, et al. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori. 1990;76(4):389–393
  45. Amesbury B, Alloway L, Hickmore E, Dewhurst G. High-dose levomepromazine (methotrimeprazine) to control nausea in carcinoid syndrome. J Palliat Care. 2004;20(2):117–118
  46. Amols W, Merritt HH. Vomiting: neural mechanisms and control by chlorpromazine. Neurology. 1955;5(9):645–653
  47. Bruera E, Brenneis M, MacDonald N. Continuous SC infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treat Rep. 1987;71:1121–1122
  48. Bruera E, Seifert L, Watanabe S, et al. Chronic nausea in advanced cancer patients: a retrospective assessment of a metoclopramide-based antiemetic regimen. J Pain Symptom Manage. 1996;11(3):147–153
  49. Burgess CL, Holman CD, Satti AG. Audit of nausea and vomiting management in palliative care hospital patients. J Pharm Pract Res. 2007;37(4):306–309
  50. Cole RM, Robinson F, Harvey L, Trethowan K, Murdoch V. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer. J Pain Symptom Manage. 1994;9(1):48–50
  51. Davis MP, Furste A. Glycopyrrolate: a useful drug in the palliation of mechanical bowel obstruction. J Pain Symptom Manage. 1999;18(3):153–154
  52. Ernst EM, Snyder AM. Perphenazine in nausea and vomiting, and anxiety states. Palliat Med J. 1958;61(3):355–359
  53. Fainsinger RL, Spachynski K, Hanson J, et al. Symptom control in terminally ill patients with malignant bowel obstruction (MBO). J Pain Symptom Manage. 1994;9:12–18
  54. Farr WC. The use of corticosteroids for symptom management in terminally ill patients. Am J Hosp Care. 1990;1:41–46
  55. Fink S, Winslow WA. Anti-emetic effect of chlorpromazine (thorazine) in cancer patients. Gastroenterology. 1955;28(5):731–735
  56. Homburger F. Perphenazine as an antiemetic agent in cancer and other chronic diseases. J Am Med Assoc. 1958;167(10):1240–1241
  57. Jackson WC, Tavernier L. Olanzapine for intractable nausea in palliative care patients. J Palliat Med. 2003;6(2):251–255
  58. Kim SW, Shin IS, Kim JM, et al. Mirtazapine for severe gastroparesis unresponsive to conventional prokinetic treatment. Psychosomatics. 2006;47(5):440–442
  59. Kumar G, Hayes KA, Clark R. Efficacy of a scheduled IV cocktail of antiemetics for the palliation of nausea and vomiting in a hospice population. Am J Hosp Palliat Care. 2008;25(3):184–189
  60. Lucas J, et al. Thorazine as aid in management of cancer patients. Proc Am A Cancer Res. 1954;30:
  61. Lundstrom S, Zachrisson U, Furst CJ. When nothing helps: propofol as sedative and antiemetic in palliative cancer care. J Pain Symptom Manage. 2005;30(6):570–577
  62. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol. 2008;6(3):119–124
  63. Mangili G, Aletti G, Frigerio . Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15(5):830–835
  64. Marks JH. Use of chlorpromazine in radiation sickness and nausea from other causes. N Engl J Med. 1954;250(23):999–1001
  65. Massacesi C, Galeazzi G. Sustained release octreotide may have a role in the treatment of malignant bowel obstruction. Palliat Med. 2006;20(7):715–716
  66. Matulonis UA, Seiden MV, Roche M, et al. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005;30(6):563–569
  67. McCawley EL, Kulasavage RJ, Warrington WR, Pasquesi TJ. The intravenous use of diphenhydramine hydrochloride in the control of nausea and vomiting. Portland Clin Bull. 1951;5(3):43–48
  68. Mercadante S, Maddaloni S. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients. J Pain Symptom Manage. 1992;7(8):496–498
  69. Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction. Palliat Med. 1993;7(4):295–299
  70. Morita T, Tei Y, Shishido H, et al. Chlorpheniramine malate as an alternative to antiemetic cyclizine. J Pain Symptom Manage. 2004;27(5):388–389
  71. Moyer JH, Kent B, Knight RW, et al. Clinical studies of an antiemetic agent, chlorpromazine. Am J Med Sci. 1954;228(2):174–189
  72. Moyer JH, Morris GC, Handley CA, Kent B, Mathews W. Observations on an effective antiemetic—chlorpromazine. AMA Arch Intern Med. 1954;94(3):497–502
  73. Nelson KA, Walsh TD. Metoclopramide in anorexia caused by cancer-associated dyspepsia syndrome (CADS). J Palliat Care. 1993;9(2):14–18
  74. Okamoto Y, Tsuneto S, Matsuda Y, et al. A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage. 2007;34(2):217–222
  75. Pae CU. Low-dose mirtazapine may be successful treatment option for severe nausea and vomiting. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1143–1145
  76. Pereira J, Bruera E. Successful management of intractable nausea with ondansetron: a case study. J Palliat Care. 1996;12(2):47–50
  77. Shinjo T, Okada M. Olanzapine use in cancer patients for refractory vomiting. Gan To Kagaku Ryoho. 2006 Mar;33(3):349–352
  78. Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage. 2003;25(6):578–582
  79. Stewart BL, Redeker AG. Emesis and hiccough; treatment with chlorpromazine. Calif Med. 1954;81(3):203–205
  80. Strohscheer I, Borasio GD. Carbamazepine-responsive paroxysmal nausea and vomiting in a patient with meningeal carcinomatosis. Palliat Med. 2006;20(5):549–550
  81. Thompson DS. Mirtazapine for the treatment of depression and nausea in breast and gynecological oncology. Psychosomatics. 2000;41(4):356–359
  82. Torres Del Toro JMT, Albertson HA. Chlorpromazine in the management of nausea and vomiting. Va Med Mon (1918). 1955 Jul;82(7):306–308
  83. Walsh TD. Antiemetic drug combinations in advanced cancer. Lancet. 1982;1(8279):1018
  84. Weschules DJ. Tolerability of the compound ABHR in hospice patients. J Palliat Med. 2005;8(6):1135–1143
  85. Wilson WL, Shane LL, Moyer JH. The use of thioperazine as an antiemetic. Antibiotic Med Clin Ther. 1959;6(7):421–425
  86. Cox J, Collins JH. Nausea and vomiting: control by thiethylperazine. Curr Ther Res Clin Exp. 1962;4:178–181
  87. Stephen CR, Dent S, Bourgeois-Gavardin M. Control of nausea and vomiting with chlorpromazine; incidence of side-effects. AMA Arch Intern Med. 1955;96(6):794–798
  88. Critchley P, Plach N, Grantham M, et al. Efficacy of haloperidol in the treatment of nausea and vomiting in the palliative patient: a systematic review. J Pain Symptom Manage. 2001;22(2):631–634[review]
  89. Dorman S, Perkins P. Droperidol for treatment of nausea and vomiting in palliative care patients (protocol). Cochrane Database Syst Rev. 2008;(1):CD006938
  90. Feuer DJ, Broadley KE. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers. Systematic Review Steering Committee. Ann Oncol. 1999;10(9):1035–1041[review]
  91. Feuer DJ, Broadley KE. Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. [review] Cochrane Database Syst Rev. 2000;(2):CD001219
  92. Frank C. Medical management of intestinal obstruction in terminal care. Can Fam Physician. 1997;43:259–265[review]
  93. Glare P, Dunwoodie D, Clark K, et al. Treatment of nausea and vomiting in terminally ill cancer patients. Drugs. 2008;68(18):2575–2590
  94. Koetter K, Kranke P. Prevention and treatment interventions for nausea and vomiting during initiation of chronic opioid therapy (protocol). Cochrane Database Syst Rev. 2008;(1):CD006959
  95. Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage. 2007;33(2):217–223[review]
  96. Moyer JH. Effective antiemetic agents. Med Clin North Am. 1957;41(2):405–432[review]
  97. Pan CX, Morrison RS, Ness J, Fugh-Berman A, Leipzig RM. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life. A systematic review. J Pain Symptom Manage. 2000;20(5):374–387[review]
  98. Perkins P, Dorman S. Haloperidol for treatment of nausea and vomiting in palliative care patients (protocol). Cochrane Database Syst Rev. 2009;(2):CD006271
  99. Rhodes VA, McDaniel RW. Nausea, vomiting, and retching: complex problems in palliative care. CA Cancer J Clin. 2001;51(4):232–248
  100. Ripamonti C, Twycross R, Baines M, et al. Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer. Support Care Cancer. 2001;9(4):223–233
  101. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. Ann Intern Med. 1997;126(5):376–380
  102. Conner PK, Moyer JH. A therapeutic appraisal of antiemetic agents. GP. 1956;14(5):125–139[review]
  103. Thompson I. The management of nausea and vomiting in palliative care. Nurs Stand. 2004;19(8):46–53
  104. Keeley P. Improving the evidence base in palliative medicine: a moral imperative. J Med Ethics. 2008;34:757–760

 The Harry R. Horvitz Center for Palliative Medicine is a World Health Organization Demonstration Project in Palliative Medicine.

PII: S0885-3924(10)00125-9

doi: 10.1016/j.jpainsymman.2009.08.010

Journal of Pain and Symptom Management
Volume 39, Issue 4 , Pages 756-767 , April 2010

Article Tools